Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report

INTRODUCTION: Although treatment options for men with metastatic castrate-resistant prostate cancer have improved in recent years, the outlook for patients remains poor, with overall survival in the region of 2 years. Response rates with chemotherapy are modest and disease progression is usually obs...

Descripción completa

Detalles Bibliográficos
Autores principales: Daverede, Luis, Ralph, Christy, Jagdev, Satinder P, Trigonis, Ioannis, Trainor, Sebastian, Harnden, Patricia, Weston, Michael, Paul, Alan, Vasudev, Naveen S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000147/
https://www.ncbi.nlm.nih.gov/pubmed/24717107
http://dx.doi.org/10.1186/1752-1947-8-122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000147/
https://www.ncbi.nlm.nih.gov/pubmed/24717107
http://dx.doi.org/10.1186/1752-1947-8-122

Ejemplares similares